Table 3.

Adjusted Changes in Urinary F2‐isoprostane Levelsa at 12 and 24 Months from Baseline by Treatment Group

ng/mg creatinine	AL N = 75	CR N = 143	p value AL vs. CR	P (time × treatment)
Primary analysis
2,3‐dinor‐iPF(2α)‐III
Change at 12 months	−0.041 ± 0.059	−0.313 ± 0.045	.0001	0.833
Change at 24 months	0.018 ± 0.075	−0.237 ± 0.058	.006
Exploratory analyses
iPF(2α)‐III
Change at 12 months	−0.012 ± 0.012	−0.042 ± 0.009	.04	0.486
Change at 24 months	−0.016 ± 0.011	−0.057 ± 0.009	.003
iPF(2α)‐VI
Change at 12  months	−0.171 ± 0.140	−0.461 ± 0.105	.08	0.846
Change at 24 months	0.115 ± 0.157	−0.213 ± 0.121	.09
8,12‐iso‐iPF(2α)‐VI
Change at 12 months	−0.303 ± 0.170	−0.751 ± 0.128	.058	0.428
Change at 24 months	−0.381 ± 0.184	−0.663 ± 0.141	.42
Isoprostane Factor
Change at 12 months	−0.098 (0.075)	−0.358 (0.057)	.004	0.974
Change at 24 months	−0.048 (0.078)	−0.311 (0.060)	.006

^aAdjusted for site, sex, BMI, and baseline values of F2‐isoprostanes